Spitalul Clinic Coltea

The medical center is at the forefront of lymphoma research, focusing on innovative treatments for relapsed/refractory follicular lymphoma and marginal zone lymphoma. The center's work in this area aims to enhance therapeutic outcomes through the comparison of novel drug combinations.

• Follicular Lymphoma
• Marginal Zone Lymphoma

By exploring the efficacy of zanubrutinib in combination with other agents, the center contributes significantly to the development of more effective lymphoma therapies.

Specializing in the intersection of chronic lymphocytic leukemia and hypogammaglobulinemia, the center conducts pivotal studies to prevent severe infections in affected patients. This research is crucial for improving the quality of life and clinical outcomes for individuals with compromised immune systems.

• Hypogammaglobulinemia
• Chronic Lymphocytic Leukemia

The center's trials on XEMBIFY offer promising insights into reducing infection rates, thereby advancing treatment protocols for immunodeficient patients.

Focusing on acute myeloid leukemia with IDH1 mutations, the center is dedicated to improving safety and tolerability of treatment regimens. This research is pivotal for patients ineligible for intensive chemotherapy, providing alternative therapeutic options.

• IDH1 Mutation-Positive AML
• Combination Therapies

Through the study of ivosidenib and azacitidine, the center is paving the way for safer and more effective treatment strategies for AML patients.

The center is pioneering research in non-small cell lung cancer, particularly focusing on MET amplified cases. This work is essential for developing targeted therapies that improve response rates in patients with advanced stages of the disease.

• MET Amplified NSCLC
• Targeted Therapy

By investigating the efficacy of telisotuzumab vedotin, the center is contributing to the advancement of personalized medicine in lung cancer treatment.